Search Results - "SANDROCK, A"

Two Randomized Phase 3 Studies of Aducanumab in Early Alzheimer’s Disease by Budd Haeberlein, Samantha, Aisen, P.S., Barkhof, F., Chalkias, S., Chen, T., Cohen, S., Dent, G., Hansson, O., Harrison, K., von Hehn, C., Iwatsubo, T., Mallinckrodt, C., Mummery, C.J., Muralidharan, K.K., Nestorov, I., Nisenbaum, L., Rajagovindan, R., Skordos, L., Tian, Y., van Dyck, C.H., Vellas, B., Wu, S., Zhu, Y., Sandrock, A.

“…Background Alzheimer’s disease is a progressive, irreversible, and fatal disease for which accumulation of amyloid beta is thought to play a key role in…”
Get full text

Radiative corrections to the average bremsstrahlung energy loss of high-energy muons by Sandrock, A., Kelner, S.R., Rhode, W.

“…High-energy muons can travel large thicknesses of matter. For underground neutrino and cosmic ray detectors the energy loss of muons has to be known accurately…”
Get full text

MRI outcomes in a placebo-controlled trial of natalizumab in relapsing MS by MILLER, D. H, SOON, D, KAPPOS, L, HUTCHINSON, M, HAVRDOVA, E, LUBLIN, F. D, GIOVANNONI, G, WAJGT, A, RUDICK, R, LYNN, F, PANZARA, M. A, SANDROCK, A. W, FERNANDO, K. T, MACMANUS, D. G, BARKER, G. J, YOUSRY, T. A, FISHER, E, O'CONNOR, P. W, PHILLIPS, J. T, POLMAN, C. H

“…In a 2-year, placebo-controlled trial (the Natalizumab Safety and Efficacy in Relapsing Remitting Multiple Sclerosis [AFFIRM] study), involving 942 patients…”
Get full text

GLANCE : Results of a phase 2, randomized, double-blind, placebo-controlled study by GOODMAN, A. D, ROSSMAN, H, PANZARA, M. A, SANDROCK, A. W, BAR-OR, A, MILLER, A, MILLER, D. H, SCHMIERER, K, LUBLIN, F, KHAN, O, BORMANN, N. M, YANG, M

“…To evaluate the safety and tolerability of natalizumab when added to glatiramer acetate (GA) in patients with relapsing multiple sclerosis. The primary outcome…”
Get full text

Contrast letter acuity as a visual component for the Multiple Sclerosis Functional Composite by BALCER, L. J, BAIER, M. L, HEIDENREICH, F. R, JACOBS, D. A, MARKOWITZ, C. E, STUART, W. H, YING, G.-S, GALETTA, S. L, MAGUIRE, M. G, CUTTER, G. R, COHEN, J. A, KOOIJMANS, M. F, SANDROCK, A. W, NANO-SCHIAVI, M. L, PFOHL, D. C, MILLS, M, BOWEN, J, FORD, C

“…Visual dysfunction is one of the most common causes of disability in multiple sclerosis (MS). The Multiple Sclerosis Functional Composite (MSFC), a new…”
Get full text

Assessing disability progression with the Multiple Sclerosis Functional Composite by Rudick, RA, Polman, CH, Cohen, JA, Walton, MK, Miller, AE, Confavreux, C, Lublin, FD, Hutchinson, M, O’Connor, PW, Schwid, SR, Balcer, LJ, Lynn, F, Panzara, MA, Sandrock, AW

“…Background The initial Multiple Sclerosis Functional Composite (MSFC) proposal was a three-part composite of quantitative measures of ambulation, upper…”
Get full text

Neutralizing antibodies and efficacy of interferon β-1a : A 4-year controlled study by KAPPOS, L, CLANET, M, SANDBERG-WOLLHEIM, M, RADUE, E. W, HARTUNG, H. P, HOHLFELD, R, XU, J, BENNETT, D, SANDROCK, A, GOELZ, S

Get full text

Diffractive Scattering of Virtual Photons on Nuclei and Its Interference with the Muon-Induced Bremsstrahlung Process by Sandrock, A., Bugaev, E. V., Kokoulin, R. P., Petrukhin, A. A.

“…Investigation of lepton propagation through matter is of importance for cosmic-ray physics and neutrino astronomy. The diffractive scattering of virtual…”
Get full text

Benefit of interferon β-1a on MSFC progression in secondary progressive MS by COHEN, J. A, CUTTER, G. R, TSAO, E. C, WHITAKER, J. N, FISCHER, J. S, GOODMAN, A. D, HEIDENREICH, F. R, KOOIJMANS, M. F, SANDROCK, A. W, RUDICK, R. A, SIMON, J. H, SIMONIAN, N. A

Get full text

Intramuscular interferon beta-1a in chronic inflammatory demyelinating polyradiculoneuropathy by HUGHES, R. A. C, GORSON, K. C, SANDROCK, A, CROS, D, GRIFFIN, J, POLLARD, J, VALLAT, J.-M, MAURER, S. L, RIESTER, K, DAVAR, G, DAWSON, K

“…Chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) shares immunologic features with multiple sclerosis (MS). Because IM interferon beta-1a (IM…”
Get full text

Elevated 1-Year Mortality Rate in Males Sustaining Low-Energy Proximal Femur Fractures and Subgroup Analysis Utilizing Age-Adjusted Charlson Comorbidity Index by Schultz, Kyle A., Westcott, Benjamin A., Barber, Kimberly R., Sandrock, Todd A.

“…Introduction: Low-energy proximal femur fractures are common in the aging population and the ability to identify patients at increased mortality risk provides…”
Get full text

Maintenance of Acetylcholine Receptor Number by Neuregulins at the Neuromuscular Junction in Vivo by Sandrock, Alfred W., Dryer, Stuart E., Rosen, Kenneth M., Gozani, Shai N., Kramer, Rainer, Theill, Lars E., Fischbach, Gerald D.

“…ARIA (for acetylcholine receptor-inducing activity), a protein purified on the basis of its ability to stimulate acetylcholine receptor (AChR) synthesis in…”
Get full text

Investigating Partially Discordant Results in Phase 3 Studies of Aducanumab by Mallinckrodt, C., Tian, Y., Aisen, P. S., Barkhof, F., Cohen, S., Dent, G., Hansson, O., Harrison, K., Iwatsubo, T., Mummery, C. J., Muralidharan, K. K., Nestorov, I., Nisenbaum, L., Rajagovindan, R., von Hehn, C., van Dyck, C. H., Vellas, B., Wu, S., Zhu, Y., Sandrock, A., Chen, T., Budd Haeberlein, Samantha

“…Objectives Efficacy and safety results from the EMERGE (NCT02484547) and ENGAGE (NCT02477800) phase 3 studies of aducanumab in early Alzheimer’s disease (AD)…”
Get full text

A Randomized, Placebo-Controlled Trial of Natalizumab for Relapsing Multiple Sclerosis by Polman, Chris H, O'Connor, Paul W, Havrdova, Eva, Hutchinson, Michael, Kappos, Ludwig, Miller, David H, Phillips, J. Theodore, Lublin, Fred D, Giovannoni, Gavin, Wajgt, Andrzej, Toal, Martin, Lynn, Frances, Panzara, Michael A, Sandrock, Alfred W

“…This placebo-controlled, randomized trial of patients with relapsing multiple sclerosis demonstrated benefits of natalizumab (an α 4 integrin antagonist) in…”
Get full text

Randomized, placebo-controlled, phase 1b study of anti-beta-amyloid antibody aducanumab (biib037) in prodromal ad/mild ad dementia: Interim results by patient subgroup by Sevigny, J, Chiao, P, Williams, L, Chen, T, Ling, Y, O’Gorman, J, Hock, C, Nitsch, R, Sandrock, A

Get full text

Estimating long-term effects of disease-modifying drug therapy in multiple sclerosis patients by Rudick, R A, Cutter, G R, Baier, M, Weinstock-Guttman, B, Mass, M K, Fisher, E, Miller, D M, Sandrock, A W

“…Two methods were used to estimate the long-term impact of disease-modifying drug therapy (DMDT) in patients with relapsing multiple sclerosis (MS) who…”
Get full text

A randomized, double-blind, dose-comparison study of weekly interferon β-1a in relapsing MS by CLANET, M, RADUE, E. W, KAPPOS, L, HARTUNG, H. P, HOHLFELD, R, SANDBERG-WOLLHEIM, M, KOOIJMANS-COUTINHO, M. F, TSAO, E. C, SANDROCK, A. W

Get full text

Gender effects on intramuscular interferon beta-1a in relapsing–remitting multiple sclerosis: analysis of 1406 patients by Rudick, RA, Kappos, L, Kinkel, R, Clanet, M, Phillips, JT, Herndon, RM, Sandrock, AW, Munschauer, FE

“…Background: We aimed to evaluate effects of gender on efficacy and safety of intramuscular (IM) interferon beta (IFNβ)-1a in patients with relapsing–remitting…”
Get full text

Introduction: Transnational Approaches to North American Regionalism by Freitag, Florian, Sandrock, Kirsten A

“…In the past ten to fifteen years, critical understandings of regions and, concomitantly, regionalist approaches to literature and culture have undergone…”
Get full text

Infusion-related hypersensitivity reactions during natalizumab treatment by PHILLIPS, J. T, O'CONNOR, P. W, LYNN, F, PANZARA, M. A, SANDROCK, A. W, HAVRDOVA, E, HUTCHINSON, M, KAPPOS, L, MILLER, D. H, POLMAN, C. H, LUBLIN, F. D, GIOVANNONI, G, WAJGT, A

Get full text